Aurobindo Pharma announced that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Potassium Chloride Extended- Release tablets, 8 mEq (600 mg) and 10 mEq (750 mg). Potassium Chloride Extended-Release tablets, a generic version of Upsher-Smith's Klor-Con Extended Release tablets.
The product will be launched in January 2019.
Potassium Chloride tablets are indicated for the treatment of hypokalemia, with or without metabolic alkalosis, in digitalis intoxication, and in hypokalemic familial periodic paralysis. The approved product has an estimated market size of ~US$ 60 million for the twelve months ending October 2018, according to IQVIA.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)